View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 17, 2020updated 12 Jul 2022 11:44am

Signant Health expands mobile patient engagement app TrialGuide

Signant Health has expanded its mobile patient engagement app, TrialGuide, with integrated virtual visit capabilities.

Signant Health has expanded its mobile patient engagement app, TrialGuide, with integrated virtual visit capabilities.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Initially launched to aid existing customers dealing with the patient-site communication challenges presented by Covid-19, virtual visits have been extended for all sponsors and CROs as the firm continues to speed up its product development roadmap to meet the evolving requirements of clinical research across the world.

Virtual visits offer more choice for patients and clinicians in enhancing the patient experience and supporting trial continuity, now and in the future.

By bringing together virtual face-to-face communication with right remote evaluations, and a direct to patient clinical supply chain, Signant Health claims to offer flexibility for patients, sites, and study teams on how, and where, clinical research is carried out.

A patient engagement solution, TrialGuide comes with features that complement virtual visits, including SMS messaging, compliance reminders, visit schedule management, caregiver support, multimedia and animated content, gamification, third-party integration with patient stipend balances, and rapid deployment capabilities.

In addition to patient engagement, Signant Health’s combined suite of patient solutions, including clinical supply chain management and endpoint quality services, are claimed to have aided customers overcome the unforeseen challenges presented by Covid-19 and prepare for new realities in clinical research by aiding trial continuity and launching clinical trials faster than before.

Signant Health chief commercial officer Ian Jennings said: “The Covid-19 pandemic illustrated how important patient-site connectivity is to the success of clinical research and our goal is to make it easier for patients to participate and communicate in trials without the technology getting in their way.

“Whether that means enabling eCOA data capture, remote consent, and video visits on a single device, deploying IRT in record time to randomise and supply patients as quickly as possible, or equipping raters with the training and tools they need to make consistent assessments remotely, we are here to support our customers who are working hard to keep their trials running and bring new treatments to people who need them worldwide.”

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena